Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fary Diop

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Expert Review of Hematology|March 22, 2018
Potential of BCL2 as a target for chronic lymphocytic leukemia treatmentRiccardo Moia, Fary Diop, Chiara Favini, et al.
Blood|January 19, 2017
Diffuse large B-cell lymphoma genotyping on the liquid biopsyDavide Rossi, Fary Diop, Elisa Spaccarotella, et al.
British Journal of Haematology|December 24, 2021
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trialAnnalisa Chiappella, Fary Diop, Claudio Agostinelli, et al.
Blood|June 24, 2016
The genetics of nodal marginal zone lymphomaValeria Spina, Hossein Khiabanian, Monica Messina, et al.
Haematologica|September 21, 2019
<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL studySimone Ferrero, Davide Rossi, Andrea Rinaldi, et al.
Blood|February 17, 2018
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphomaValeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Review of Hematology|March 22, 2018
Potential of BCL2 as a target for chronic lymphocytic leukemia treatmentRiccardo Moia, Fary Diop, Chiara Favini, et al.
Blood|January 19, 2017
Diffuse large B-cell lymphoma genotyping on the liquid biopsyDavide Rossi, Fary Diop, Elisa Spaccarotella, et al.
British Journal of Haematology|December 24, 2021
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trialAnnalisa Chiappella, Fary Diop, Claudio Agostinelli, et al.
Blood|June 24, 2016
The genetics of nodal marginal zone lymphomaValeria Spina, Hossein Khiabanian, Monica Messina, et al.
Haematologica|September 21, 2019
<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL studySimone Ferrero, Davide Rossi, Andrea Rinaldi, et al.
Blood|February 17, 2018
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphomaValeria Spina, Alessio Bruscaggin, Annarosa Cuccaro, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Pageof 1